Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials

Frontiers in Cardiovascular Medicine - Switzerland
doi 10.3389/fcvm.2019.00014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease

2015English

Planning and Interpreting the Sample Size of Trials With Multiple Outcomes

Journal of Orthodontics
Orthodontics
2019English

Advances in Dyslipidemia Management for Prevention of Atherosclerosis: PCSK9 Monoclonal Antibody Therapy and Beyond

Cardiovascular Diagnosis and Therapy
Cardiovascular MedicineCardiology
2017English

Update in Diabetes and Cardiovascular Disease: Synthesizing the Evidence From Recent Trials of Glycemic Control to Prevent Cardiovascular Disease

Current Opinion in Lipidology
NutritionGeneticsCell BiologyMolecular BiologyCardiologyEndocrinologyCardiovascular MedicineDieteticsMetabolismDiabetes
2010English

Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials

Atherosclerosis
Cardiovascular MedicineCardiology
2019English

The Therapeutic Monoclonal Antibody Market

mAbs
AllergyImmunology
2015English

Cardiovascular Outcomes in Trials of Oral Diabetes Medications

Archives of Internal Medicine
2008English

Successful Recruitment to Trials: Findings From the SCIMITAR+ Trial

Trials
MedicinePharmacology
2018English

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors: Shaping the Future After the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy